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ABSTRACT

In Vitro Simulation of Microgravity Induced Muscle Loss Successfully Increases
Expression of Key In Vivo Atrophy Markers
by
Charles P. Harding, Master of Science
Utah State University, 2018

Major Professor: Dr. Elizabeth Vargis
Department: Biological Engineering

Muscular atrophy, defined as the loss of muscle tissue, is a serious issue for
immobilized patients on Earth and in human spaceflight, where microgravity prevents
normal muscle loading. In vitro modeling is an important step in understanding atrophy
mechanisms and testing countermeasures before animal trials. The most ideal
environment for modeling must be empirically determined to best mimic known
responses in vivo.
To simulate microgravity conditions, murine C2C12 myoblasts were cultured in a
rotary cell culture system (RCCS). Alginate encapsulation was compared against
polystyrene microcarrier beads as a substrate for culturing these adherent muscle cells.
Changes after culture under simulated microgravity were characterized by assessing
mRNA expression of MuRF1, MAFbx, Caspase 3, Akt2, mTOR, Ankrd1, and Foxo3.
Protein concentration of myosin heavy chain 4 (Myh4) was used as a differentiation
marker. Cell morphology and substrate structure were evaluated with brightfield and
fluorescent imaging.
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Differentiated C2C12 cells encapsulated in alginate had a significant increase in
only MuRF1 following simulated microgravity culture and were morphologically
dissimilar to normal cultured muscle tissue. On the other hand, C2C12 cells cultured on
polystyrene microcarriers had significantly increased expression of MuRF1, Caspase 3,
and Foxo3 and easily identifiable multi-nucleated myotubes. The extent of differentiation
was higher in simulated microgravity and protein synthesis more active with increased
Myh4, Akt2, and mTOR. The in vitro microcarrier model described herein significantly
increases expression of several of the same atrophy markers as in vivo models. However,
unlike animal models, MAFbx and Ankrd1 were not significantly increased and the fold
change in MuRF1 and Foxo3 was lower than expected.
Using a standard commercially available RCCS, the substrates and culture
methods described only partially model changes in mRNAs associated with atrophy in
vivo. Nevertheless, our results in vitro are highly significant for MuRF1 (p<0.01), Foxo3
(p<0.01), and Caspase 3 (p<0.001), indicating that with further development, simulated
microgravity systems may present a promising system for investigation of atrophy
pathways and first-step design and selection of novel therapeutics necessary to ensure
astronaut health and fitness during long-term spaceflight. (97 pages)
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PUBLIC ABSTRACT
In Vitro Simulation of Microgravity Induced Muscle Loss Successfully Increases
Expression of Key In Vivo Atrophy Markers
Charles P. Harding
Muscle loss from lack of activity is a serious issue for immobilized patients on
Earth and in human spaceflight, where the low gravity environment prevents normal
muscle activity. Simulating muscle loss in cultured cells is an important step in
understanding how this condition occurs. This work evaluates different means of
simulating muscle loss and selects the one that most closely mimics the cellular responses
seen in animals and humans.
To simulate the microgravity environment of spaceflight, mouse skeletal muscle
cells were grown in a rotary cell culture system (RCCS). Growing the cells within a
natural gelled substrate was compared against growing them on the surface of small
plastic beads. Changes after culture under simulated microgravity were characterized by
assessing proteins and genes known to change during muscle loss. The structure of the
cells was also evaluated by microscopy.
The mouse skeletal muscle cells grown on plastic beads in the RCCS had
significant changes in multiple key genes associated with muscle loss and demonstrated
physical characteristics expected of mature tissue in live animals. This model is a
valuable platform for exploring muscle loss mechanisms and testing new drugs.
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CHAPTER 1
INTRODUCTION
Motivation and Scope

Skeletal muscle loses significant strength and mass during extended periods of
inactivity, with losses of 40% reported after 6 months in orbit[1]. Not limited to
spaceflight, the causes of inactivity also include immobilization of broken limbs,
paralysis, and bed rest. Reducing muscle loss associated with inactivity is critical for
preserving the strength and endurance of astronauts, especially with future long-term
missions planned for Mars. Muscle mass loss for short duration missions ranges from 1020%, compared to 30-50% for long duration missions[2, 3]. To reduce these risks, flight
protocol at the National Aeronautics and Space Administration (NASA) mandates that
crew members exercise on missions lasting over 10 days; however, loss of strength and
muscle mass has been reported after only 5 days[4, 5]. Earth-bound patients would also
benefit from faster recovery times and reduced need for physical therapy following
serious injuries. Approximately 40-50% of total body mass is skeletal muscle and its loss
can induce numerous detrimental physiological changes, including reduced power, lower
endurance, and atypical reflex responses[6, 7]. While many promising anti-atrophy
compounds have been identified, testing them in actual spaceflight conditions would be
prohibitively expensive and time consuming.
Modeling the atrophy-inducing microgravity environment of space in a groundbased laboratory has several challenges. The multiple animal models of atrophy,
including hindlimb unloading, limb casting, tendonectomy, and nerve blocking only
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affect a small portion of the body. While localized atrophy effects can be studied using
these methods, systemic effects of whole body atrophy, as would be experienced in
spaceflight, are not accurately modeled. Localized, tissue-specific atrophy can also be
modeled in vitro at a significantly lower cost and without the regulatory oversight
necessary for animal models. Clinostats and rotary cell culture systems move the cells
such that the sum of gravitational vectors over time is approximately zero. However, the
growth substrate and culture process must be optimized for the selected cell line to
maximize changes in the desired atrophy markers versus the control.
Here, we have developed a ground-based model that mimics microgravityinduced expression of the mRNA atrophy markers MuRF1, MAFbx, and Caspase 3 in
vitro using a rotary cell culture system and the C2C12 mouse skeletal muscle cell line.
This model provides consistent and significant increases in the selected markers and a
means of screening anti-atrophy therapeutics prior to testing in vivo. Additionally,
external radiation can be applied to the system to more accurately mimic the spaceflight
environment. We expect the model will be valuable for probing atrophy mechanisms and
expediting the search for pharmaceuticals that enable long-duration spaceflight missions
and improve patient outlook.

Organization

This thesis describes development of a model for mimicking atrophy of skeletal
muscle cells in vitro, including growth substrate selection, application of low-dose
radiation, and metrics for morphology, gas transfer, amino acids, metabolites, proteins,
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and mRNAs. Chapter 2 provides a background on the mechanisms of spaceflight atrophy
and a literature review of atrophy modeling in vivo and in vitro. Additionally, it
highlights where the model developed herein fits into the current body of literature.
Chapter 3 details the preliminary work in developing the microgravity model.
Selection of an appropriate control vessel, growth substrate, and culture methodology is
discussed. Use of amino acid and metabolite analysis for distinguishing between normal
gravity controls and simulated microgravity conditions is evaluated. Finally, addition of
low-dose gamma radiation is investigated.
Chapter 4 is a manuscript prepared for the Utah NASA Space Grant Consortium.
Chapter 5 contains the final model and metrics developed in this thesis, as will be
submitted for publication. Chapter 6 summarizes the main findings of this thesis and
concludes with future work involving anti-atrophy compounds, higher-dose radiation,
and additional cell lines.
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CHAPTER 2
BACKGROUND AND LITERATURE REVIEW
Mechanisms of spaceflight atrophy

Astronauts experience significant muscle loss in spaceflight despite the current
International Space Station exercise program[8]. Disuse, reduced protein synthesis, and
reduced motor neuron activity all contribute to loss of muscle tissue and strength in
spaceflight[6]. The degree of atrophy is dependent on anatomical region and duration of
exposure to the microgravity environment. Short duration missions can result in a 1020% loss of muscle mass, where losses in long duration missions can range from 3050%[2, 3]. Atrophy is more severe for muscles responsible for maintaining posture under
normal gravity, with the intrinsic back muscles losing 10.3% volume compared to 3.9%
for calf muscles after 8 days of spaceflight[2, 9]. Atrophy affects cardiac muscle in
addition to skeletal muscle, with a decrease in left ventricular mass of 12% following 10
days of spaceflight[10]. Preventing muscle atrophy would preserve the strength and
endurance of astronauts and help enable longer duration space travel and exploration.
The mRNA atrophy markers MuRF1, MAFbx, and Caspase 3 are all critical
components of muscle tissue breakdown via the ubiquitin proteasome pathway. In this
pathway, ubiquitin—a polypeptide co-factor—attaches to the protein to be degraded, the
complex is recognized by the 26S proteasome, then broken down into its constituent
amino acids[11]. There are three enzymes involved in attaching ubiquitin to the protein,
E1, E2, and E3. The E3 ubiquitin ligases are the most diverse group, with up to 1000
different ligases serving this role in mammals[11]. Two key E3 ubiquitin ligases involved
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in attaching ubiquitin to proteins are MuRF1 and MAFbx, both upregulated in a wide
range of atrophy models including denervation, hindlimb unloading, immobilization, bed
rest, multiple diseases, spaceflight, and aging[12, 13]. MAFbx and MuRF1 aren’t
upregulated for all types of atrophy. Contrary to atrophy from immobilization,
sarcopenia, or age-related muscle loss, results in a down-regulation of these key ubiquitin
ligases, indicating that multiple mechanisms need to be investigated for a total picture of
muscle loss[14]. This thesis focuses on loss from a simulated microgravity environment.
The role of the third mRNA marker, Caspase 3, comes into play in the first stages
of atrophy. Intact muscle fibers can’t be degraded by the ubiquitin proteasome system
and must be broken down before MuRF1 and MAFbx can act. Reactive oxygen species—
increased during muscular atrophy—upregulate calpains, which degrade multiple musclerelated proteins, including titin, nebulin, actin, and myosin[7]. Reactive oxygen species
(ROS) also increase Caspase 3, which breaks down actomyosin complexes in the muscle
tissue[7, 11]. Treatment with vitamin-E, a potent antioxidant, significantly reduced
Caspase 3 expression in mice subject to 14 days unloading, but did not bring the
expression level all the way down to the control[15]. A cell culture model that
successfully mimics in vivo atrophy should demonstrate upregulation of Caspase 3 for the
initial stages of muscle breakdown, as well as MuRF1 and MAFbx for the later stages of
protein recycling via the ubiquitin proteasome system.
Blocking the ubiquitin proteasome system can have therapeutic effects, but is not
a feasible method for attenuating atrophy. Antigenic peptides produced following protein
degradation are presented to lymphocytes, which then produce antibodies[11]. One such
proteasome inhibitor, Bortezomib, is an effective chemotherapeutic agent, but also acts as
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an immunosuppressant[16]. Likewise, blocking Caspase 3 to prevent muscle atrophy is
not a viable solution. Caspase 3 inhibited C2C12 cells and primary myoblasts from
Caspase 3 null mice displayed markedly reduced differentiation[17].
In addition to upregulating Caspase 3, ROS play an additional role in muscle
atrophy via degradation of muscle fibers[18]. As astronauts travel past the protection of
the Earth’s magnetic field, they experience increased radiation levels which generate
ROS by the radiolysis of water[19]. Even after returning to Earth, ROS generated by
microgravity and irradiation can continue to disrupt cellular systems. Harmful radiation
in space primarily comes in two forms, gamma rays and high energy heavy ions[20].
Radiation intensity fluctuates depending on solar activity and proximity to the Earth. The
lowest radiation dose rates occur when in close proximity to the Earth and during the
solar maximum[20]. Gamma rays are a form of electromagnetic radiation with no mass
while high energy heavy ions are atomic nuclei stripped of electrons and moving at
relativistic velocities. Some high energy heavy ions are produced by the Sun, but most
come from distant supernovae.
Relative biological effectiveness (RBE) is a measure of how damaging a
particular type of radiation is to living tissue. Gamma radiation is assigned an RBE of 1
by definition. High energy heavy ions can have RBE values ranging from 20-40,
indicating significantly more tissue damage for an equivalent dose[21]. Although high
energy heavy ions present a greater health hazard in spaceflight, they are difficult to
simulate in a laboratory and require large particle accelerators to produce. In contrast,
gamma radiation sources are relatively inexpensive and a large body of data exists
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regarding epidemiological studies in radiation-exposed humans, rodents, and non-human
primates.
NASA limits astronaut radiation exposure to levels that correspond with a 3%
increase in fatal cancer risk[22]. Long-term missions beyond low Earth orbit, such as a
journey to Mars, exceed this limit within a single mission and increase the risk of
developing cancer[20]. Due to the highly penetrating nature of high energy ions in
cosmic radiation, shielding the spacecraft is not economically feasible[20]. Biological
countermeasures to radiation damage and increased cancer risk provide an attractive
alternative to heavy and costly shielding.
One cellular response that counters radiation damage is the up-regulation of heme
oxygenase-1 (HO-1)[23, 24]. HO-1 is induced in response to oxidative stress and
combats this stress in part by degrading heme into biliverdin-IXα, a natural antioxidant
and anti-inflammatory[25]. Artificial induction of HO-1 has demonstrated protective
effects against ionizing radiation in multiple tissue types[24, 26]. Another promising
atrophy and radiation countermeasure is vitamin E. The antioxidant effects of vitamin E
scavenge free radicals and reduce expression of calpains and Caspase 3, -9, and -12,
reducing muscular atrophy due to immobilization and unloading[27, 28]. In addition to
preventing muscle loss, vitamin E also preserves bone mass and strength following
unloading[29]. Several forms of vitamin E have demonstrated radioprotective effects,
including α-tocopherol, δ-tocotrienol, and γ-tocotrienol[30–32].
In summary, muscular atrophy is a complex process involving multiple pathways
interlinked with other critical cellular functions. Understanding how modifying one
pathway might influence other systems is vital in development of therapeutics. In vitro
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modeling, as described in this thesis, is well suited to evaluating changes in cell
metabolism and mRNA expression induced by experimental drugs.

Atrophy modeling in vivo

A classic method for simulating weightlessness is the hind limb unloading rodent
model, developed at NASA in the 1970’s[33]. In this model, the rodent is affixed in a
harness or tail traction device such that the hind limbs are elevated at a 30° angle[33].
The resulting unloading induces differential muscle atrophy in the hind limbs and
cephalic fluid shift similar to real microgravity conditions[33]. Three commonly
measured mRNAs in muscle loss modeling are muscle RING finger-1 (MuRF1), muscle
atrophy F-box (MAFbx), and Caspase 3, all upregulated in numerous rodent models of
muscular atrophy including disease, immobilization, hind limb unloading, as well as
spaceflight[12, 15, 34–45]. Following hind limb unloading, knockout mice lacking
MuRF1 and MAFbx display significantly less atrophy than wild type mice, highlighting
the importance of those ligases in the mechanisms underlying muscle loss[12, 35].
Cages for hindlimb unloading must be designed to accommodate the specific
requirements of each experiment. Metabolism can be monitored by attaching a specially
designed urine and feces separator to the bottom of the cage[46]. If radiation will also be
administered, the animal must either be moved to a smaller container that restricts
movement, thereby ensuring the dose is consistent and localized, or a lower dose
radiation source must be attached to the cage itself[47, 48]. A lower activity radiation
source, such as a cobalt 57 plate under the cage, can provide a whole-body dose for the
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duration of the experiment. This constant, lower level dose is more similar to spaceflight
than periodic acute doses. However, if additional types of radiation, such a proton or
heavy ion, are desired, the animals must be moved to a synchrotron or particle accelerator
and an acute dose administered.
Animal models have the benefit of providing a variety of tissue types following
completion of microgravity simulation and irradiation. In addition to muscle tissue,
hindlimb unloading and irradiation studies have investigated bone, cardiovascular
function, immunology, renal function, neurology, reproductive systems, and oxidative
stress[49–53].
In conclusion, animal models using hindlimb unloading and other immobilization
methods are a common and effective means of simulating multiple changes, including
atrophy from the microgravity environment. However, ground-based animal models are
more time consuming, more expensive, and are subject to more regulation than cell
culture models, providing strong motivation to develop other methods. Newly developed
therapeutics can be effectively screened with smaller quantities in cell culture models and
safe dose ranges established prior to testing in vivo.

Atrophy modeling in vitro

In vitro simulation of microgravity can be conducted with rotary culture systems
and 3D random positioning machines or clinostats[54, 55]. In vitro microgravity
simulation has the benefits of lower costs and fewer regulatory concerns compared to
animal models. For use in drug development, the quantity of test compound required to
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elicit a response is lower for small in vitro systems, conserving therapeutics that may be
difficult to produce at early stages of development.

Figure 1. Microcarrier clusters with C2C12 cells suspended in the RCCS.

Atrophic conditions can be generated in ground-based laboratories with a rotary
cell culture system (RCCS), developed by Synthecon Inc. in conjunction with NASA to
simulate microgravity[54]. Microgravity is simulated by the rotational motion of the
vessel maintaining cells at their terminal settling velocity, similar to what astronauts
experience in orbit around Earth [Figure 1]. Fluid flow in the RCCS had been designed to
provide a low shear environment[54]. The settling velocity is described by the equation
𝑣𝑠 =

2
2𝑔(𝜌𝑎 −𝜌)𝑅𝑎

9𝜇

, where 𝜌𝑎 is the density of the cell aggregate, 𝜌 is the density of the

culture media, Ra is the radius of the cell aggregate, and µ is the fluid viscosity[56].
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When the substrates are maintained at their terminal settling velocity, the force of gravity
𝐹𝑔 is described by Stoke’s Law.
4
𝐹𝑔 = (𝜌𝑎 − 𝜌)𝑔 𝜋𝑅 3
3
The resulting 𝐹𝑔 is balanced by the drag force from the rotating fluid, resulting in a net
force of zero. Since 𝑔 and 𝑅 are constant at any given moment, the ratio of 𝐹𝑔 in the
RCCS to the normal force of gravity can be simplified to express how many times normal
gravity (𝑋𝑔) is produced within the system.
4
4
(𝜌𝑎 − 𝜌)𝑔 𝜋𝑅 3 (𝜌𝑎 − 𝜌)𝑔 𝜋𝑅 3 𝜌𝑎 − 𝜌
𝐹𝑔 𝑅𝐶𝐶𝑆
3
3
𝑋𝑔 =
=
=
=
4
𝐹 𝑔 𝑁𝑜𝑟𝑚𝑎𝑙
𝑚×𝑎
𝜌𝑎
(𝜌𝑎 × 3 𝜋𝑅 3 )𝑔
As a result, the final force of gravity on the cells is dependent entirely on the density of
the substrate and surrounding fluid. To minimize the force of gravity, a cell culture
substrate with a density close to that of water should be selected.
The RCCS has been used to simulate microgravity in a variety of cell types,
including lymphocytes, osteoblasts, and myoblasts[57–59]. The C2C12 cell line used in
the experiment presented herein is a mouse myoblast line that can differentiate into
contractile skeletal muscle fibers. The cells can be tested in their undifferentiated state to
investigate effects on developing tissue, as well as in their differentiated state to
investigate effects on mature tissue. First cultured in 1977, the C2C12 cell line produces
many of the same proteins and mRNAs as human muscle tissue, making it a suitable
analog for investigation of atrophic conditions[60].
As an adherent cell line, C2C12 cells require a substrate for growth. A threedimensional scaffold suitable for culture of adherent cell lines such as C2C12’s can be
formed from a wide variety of synthetic and naturally occurring hydrogels[61]. Selection
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of a scaffold should include considerations for compatibility with the desired cell type,
physical characteristics, diffusion rate, and ease of gelling and dissolution. Scaffolds such
as poly(lactide-co-glycolide) (PLG) have good mechanical properties and excellent
biocompatibility for use in vivo, but harsh processing conditions makes encapsulation of
viable cells challenging[61]. Other synthetic polymers such as poly(ethylene oxide)
(PEO) and poly(vinyl alcohol) (PVA) have established medical applications for tissue
engineering and drug delivery, but photo-crosslinking of PEO with UV light and PVA
with repeated freeze-thaw cycles or glutaraldehyde would damage encapsulated cells[61].
In contrast, the naturally occurring hydrogel alginate has well established uses for cell
encapsulation due to low toxicity and gentle gelling conditions[61–66]. The high porosity
of alginate hydrogels is advantageous for maximizing diffusion rates and ensuring
adequate exchange of nutrients and waste products with the surrounding culture
media[62]. Dissolution of alginate hydrogels for cell harvesting can be accomplished
with a neutral buffered solution of sodium citrate.
Encapsulation of mammalian cells in alginate hydrogels to generate 3D cultures
has been performed on many cell types, including stromal vascular cells, Leydig cells,
baby hamster kidney cells, epithelial cells, fibroblasts, and myoblasts[63–66]. Diffusion
of nutrients through the alginate bead is a function of molecule size and the percentage of
alginate, with smaller molecules and lower alginate percentages resulting in faster
diffusion[67]. The percentage alginate used for encapsulation can be varied between 1.53% (w/v) depending on the cell type and desired mechanical properties[63–66, 68]. To
preserve bead integrity in the dynamic RCCS environment, we elected to encapsulate
cells at the upper end of the range to maximize mechanical strength of the beads [Figure
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2][62]. Mechanical stability of alginate beads can also be modified by complexing with
chitosan[63]. Additionally, alginate beads can be formed in various sizes by changing the
gauge of the needle used for extrusion. In contrast with microcarrier beads, which are
limited to seeding with undifferentiated cells, alginate encapsulation can be performed on
both undifferentiated and differentiated muscle cells. The tunable properties and low cost
of alginate hydrogels make them an attractive substrate for 3D cultures.

Figure 2. C2C12 cells suspended in 3% w/v alginate solidifying in 200 mM CaCl2,
10mM HEPES

Another option for culturing adherent cells in the suspension environment of the
RCCS is microcarriers, small synthetic beads with a suitable surface chemistry [Figure
3]. The ease of scalability makes microcarriers an attractive substrate for producing large
quantities of cells for therapeutic applications[69, 70]. A wide variety of surface
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chemistries are available from suppliers to tailor the beads for specific cell types and
culture conditions[69]. Successful culture of muscle cells on microcarriers has been
reported with dextran, collagen, and polystyrene surfaces[56, 71, 72]. While a more
expensive substrate than alginate, the variety of commercially available bead types, ease
of use and facile scalability make microcarriers an industry standard for suspension
culture of adherent cells.

Figure 3. HyQ Sphere Pplus 102-L Polystyrene microcarriers

Conclusion

Previously published work with muscle cells, including C2C12s, in simulated
microgravity focused on changes in differentiation induced by culture in the RCCS[56,
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59, 73]. To the best of the authors’ knowledge, no previously published work has
investigated changes in atrophy-specific mRNAs with muscle cell culture in the RCCS.
The work presented in this thesis combines the mRNA analytics of in vivo atrophy
modeling with the in vitro RCCS, supporting use of cultured muscle cells in
investigations of atrophic mechanisms.
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CHAPTER 3
PRELIMINARY WORK
Overview

This section covers selection of the control cell culture vessels and alginate
encapsulation conditions used in Chapters 4 and 5. Additionally, metrics for
distinguishing between control and simulated microgravity conditions are discussed. We
initially sought to use analysis of cell metabolites and amino acids to determine culture
status. However, these methods did not have sufficient resolution to distinguish between
conditions. Nevertheless, key results of branch chain amino acid levels and glucose
consumption are presented to demonstrate typical concentrations under simulated
microgravity conditions.

Selection of static control vessel for microcarriers

A control vessel in a simulated microgravity cell culture model should meet three
criteria: same volume as RCCS vessels, suitable surface chemistry, and single
gravitational vector. An identical media volume is needed to control for the quantity of
nutrients available to the cells. A low adhesion surface chemistry in the control vessel is
critical in microcarrier cultures to force cells to grow only on the microcarrier beads. Use
of a cell culture treated flask with microcarriers provides a larger surface area for growth
than would be available in the RCCS and results in microcarriers stuck to the surface of
the flask. Finally, the control vessel should either be static or agitated in a manner that
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results in a single primary gravitational vector, such as an orbital shaker at low speed or
rocker plate.
Two vessel types were evaluated for culture of microcarriers as a normal-gravity
control, the Nunc OptiCell cartridge and the Corning ultra-low attachment flask [Figure
4]. Both vessels have a 10 mL working volume, equivalent to that of the vessels used
with the RCCS. The OptiCell cartridge has the advantage of a gas-permeable membrane
with a high surface area to volume ratio, resulting in increased oxygen saturation during
the earlier stages of the culture [Figure 5]. However, the cartridge requires all fluid
handling be done through a syringe needle, which is easily clogged by the microcarrier
beads. Due to the clogging, added expense of using syringes instead of pipette tips, and
dissimilar dissolved oxygen profile compares to the RCCS, T25 flasks with an ultra-low
attachment surface were selected as the normal gravity control vessels.
Initially, the control flasks were cultured on a rocker plate to account for fluid
motion in the RCCS. However, the rocker plate forced all the microcarrier beads into a
single large mass not representative of the cluster sizes in the RCCS. A low speed orbital
shaker produced a similar result. When properly filled and absent of air bubbles, shear
forces from fluid motion in the RCCS are negligible and selecting a control with similar
bead cluster morphology is preferred[54]. Therefore, static ultra-low attachment flasks
were selected as the optimum control.
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Figure 4. OptiCell cartridge (top) compared to a standard T25 (bottom) for static normalgravity controls.
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Figure 5. Oxygen saturation of cell culture media in each vessel, n=1.
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Optimization of encapsulation conditions

Encapsulating and immobilizing cells within an alginate hydrogel is another
means of generating a 3D cell mass. Unlike microcarriers, where monolayers of cells
freely grow on the surface of the substrate, alginate encapsulation locks cells in place
within the substrate. The conditions under which cells are encapsulated, including cell
density, alginate percentage, and the use of additives such as chitosan can all influence
the culture performance. This section discusses the steps taken to determine the
encapsulation parameters best suited for use with the RCCS.
The cell density for encapsulation was selected to maximize cell-cell contact
within the alginate bead while maintaining bead integrity. It was observed that cells have
difficulty spreading through the bead, likely due to the high density of the 3% w/v
alginate substrate. While the percentage alginate used for encapsulation can be varied
between 1.5-3% (w/v), we elected to encapsulate cells at the upper end of this range to
maximize mechanical strength of the beads in the dynamic RCSC environment[62–66,
68].
To limit the distance the cells needed to spread before contacting another cell,
seeding density optimization was performed. Undifferentiated cells were encapsulated at
densities of 0.25, 0.5, 1, and 10x106 cells/mL alginate. Differentiated cells were
encapsulated following 10 days of culture in standard tissue culture flasks, after which
there were removed with a cell scraper and encapsulated at 75 or 150 cm2 of flask area
per mL of alginate.

20

A syringe pump with a multi-syringe head was used to form alginate beads at
multiple encapsulation densities simultaneously [Figure 6]. With a 19 gauge needle and a
flow rate of 2 mL/min, the average bead size was 3251±103 µm, n=10. The size of the
beads formed with this method is too large to be aspirated with a serological pipette,
requiring the beads to be poured into their culture containers. Use of smaller needles was
attempted, but the high cell density resulted in frequent clogging, especially with
differentiated cells.

Figure 6. Syringe pump setup for formation of multiple cell-alginate ratio beads.

With undifferentiated cells, the appearance of the beads under brightfield imaging
became darker as encapsulation density increased [Figure 7]. Even at the upper end
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concentration of 10x106 cells/mL, bead shape was highly spherical. The highest cell
density also affords the greatest chance of cell-cell contact necessary for differentiation
into multi-nucleated myotubes.
With differentiated cells, at a density of 75 cm2/mL the beads were mostly full of
tissue and still maintained circularity [Figure 8]. At a higher density of 150 cm2/mL, the
beads did not harden into spherical shapes and some droplets broke apart on contact with
the CaCl2 solidification buffer [Figure 9]. Therefore, 75 cm2 of flask area per milliliter of
alginate was selected as the ratio for encapsulation of differentiated cells.
The standard alginate croslinking process solidifies the hydrogel, but the beads
remain fragile and may be damaged by mechanical forces in the RCCS. Use of chitosan
to coat the beads was investigated as a means of improving mechanical durability.
Confluent and differentiated C2C12 cells were scraped and encapsulated in alginate
beads at a density of 75cm2/mL alginate. Alginate beads were solidified both with and
without cells in either a 0.2 M CaCl2 solution or a 0.5% chitosan solution with 13 mM
HEPES and 1.5% (0.135 M) CaCl2[63]. 30 alginate beads were created for each
condition. The media was DMEM 10% FBS and was not changed over the duration of
the experiment. After 15 days, the beads were removed from the RCCS vessels and
imaged. The –Cells +Chitosan vessel had 28/30 beads still present. All other conditions
had all 30 beads intact. Significant debris was observed in the +Cells +Chitosan condition
[Figure 10 B]. The debris was not present in the +Cells –Chitosan condition [Figure 10
A]. No significant difference was observed in the condition of the beads themselves, but
the presence of debris and loss of two beads suggests that 0.5% chitosan may negatively
affect bead durability. Chitosan was not used in subsequent experiments.
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Figure 7. Encapsulation of undifferentiated C2C12 cells at 0.25 (A), 0.5 (B), 1 (C), and
10 (D) x106 cells/mL alginate. Scale bar = 1000 µm.
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Figure 8. Differentiated cells encapsulated at 75 cm2/mL alginate

Figure 9. Differentiated cells encapsulated at 150 cm2/mL alginate
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Figure 10. Encapsulated differentiated cells after 15 days of culture in beads without (A)
and with (B) chitosan.

Amino acid and glucose analysis

Amino acid concentrations in cell culture media can provide insight into cell
metabolism and pathways affected by the experimental conditions. The cell culture
process requires a media exchange every 3 days, so data on nutrient consumption is
limited to that same timeframe. Preliminary investigation of amino acid levels was
performed on day 9 to allow sufficient time for differentiation. A Waters Alliance 2695
high performance liquid chromatography (HPLC) system was used to analyze alanine
and the branch chain amino acids (BCAAs) leucine, isoleucine, and valine. Alanine, not
present in DMEM, is secreted into the bloodstream by muscle fibers while BCAAs are
oxidized for nutrients[74, 75]. Lower alanine production and BCAA consumption would
indicate decreased metabolic activity, expected in simulated microgravity.
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Alanine was produced by the cells in both experimental conditions, but less was
produced in the simulated microgravity condition [Figure 11]. After 9 days, BCAA
concentrations were lower in the normal gravity control, indicating higher cell
metabolism compared to the simulated microgravity condition. [Figure 11]. Due to small
differences between the simulated microgravity condition and DMEM, as well as the
regular changing of media introducing variability to the system, HPLC was not used in
the following chapters. Instead, qRT-PCR was selected to maximize sensitivity and focus
on atrophy markers supported by a large body of literature.
Metabolic activity of the cells was also investigated by measuring glucose
consumption with a Nova Biomedical BioProfile FLEX. A decrease in consumption
would indicate attenuated metabolism. Glucose consumption decreased sharply between
days 6 and 9 for alginate encapsulated cells, while increasing for cells cultured on
microcarriers [Figure 12]. Conversely, glucose consumption increased during this period
for the microcarrier condition, indicating a higher metabolic rate and more cell growth.
The consumption trends are similar for each substrate’s respective normal gravity and
simulated microgravity conditions [Figure 12].

Concentration (nM)

26

10
9
8
7
6
5
4
3
2
1
0
LEU

ILE

VAL

ALA

Amino Acid
Normal Gravity Control

Simulated Microgravity

DMEM

Figure 11. Amino acid levels post-differentiation on day 9. Alanine not present in
DMEM.
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Figure 12. Glucose consumption, as measured by the difference between spent media
and fresh DMEM (n=4, error bars are standard deviation).

Conclusion

With amino acid results potentially affected by variations in residual media
volume during periodic media changes and similar glucose consumption profiles between
RCCS and control conditions, highly sensitive qRT-PCR was selected as the preferred
metric for use in Chapter 5. For microcarriers, ultra-low attachment flasks were selected
over the OptiCell cartridge; the oxygen profile was similar to the RCCS and bead clusters
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were not damaged during liquid handling. The optimized encapsulation density of 10x10 6
cells/mL and 75 cm2/mL of alginate was used for subsequent work with undifferentiated
and differentiated cells, respectively. Chitosan was not necessary for the mechanical
stability of the alginate beads, as 100% of beads without alginate were still intact after the
15-day culture period. With the culture parameters established in this chapter and qRTPCR identified as a necessary metric, subsequent work in Chapter 5 focused on
comparing microcarriers with alginate encapsulation.
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CHAPTER 4
UTAH NASA SPACE GRANT CONSORTIUM PAPER
In Vitro Modeling of Microgravity-Induced Muscle Atrophy and Spaceflight Radiation

Abstract
Muscular atrophy, defined as the loss of muscle tissue, is a serious issue for
immobilized patients on Earth and in human spaceflight, where microgravity prevents
normal muscle loading. A major factor in muscular atrophy is oxidative stress, which is
amplified not only by muscle disuse, but also by the increased levels of ionizing radiation
in spaceflight. Additionally, elevated radiation exposure can damage DNA, increasing
cancer risk.
To model oxidative stress and DNA damage generated by conditions on the
International Space Station, murine C2C12 myoblasts were cultured in a rotary cell
culture system irradiated by cesium-137. Changes due to the spaceflight model were
characterized with fluorescent imaging, amino acid analysis, and enzyme linked
immunosorbent assay for heme oxygenase 1. Fluorescent imaging was performed to
assess viability, lipid peroxidation, and DNA damage.
Minor DNA damage was observed in cells exposed to 20 µCi cesium-137 for 15
days. No significant differences in viability or lipid peroxidation were noted. Exposure to
radiation decreased intracellular heme oxygenase 1 and extracellular alanine, but did not
affect branch chain amino acids. Investigation of stronger radiation sources and extended
culture time is ongoing. We anticipate that radiation will exacerbate the atrophic effects
of microgravity on muscle cells. Simulation of microgravity and spaceflight radiation will
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provide a valuable platform for drug discovery and an understanding of the progression
from normal to disease state.
Introduction
Muscular atrophy due to disuse is a serious issue for individuals subject to bed
rest or prolonged immobilization, as well as in human spaceflight, where microgravity
prevents normal muscle loading. Atrophy affects cardiac muscle in addition to skeletal
muscle, with a decrease in left ventricular mass of 8% and 12% following 6 weeks of bed
rest and 10 days of spaceflight, respectively[10]. Preventing cardiac and skeletal muscle
atrophy would preserve the strength and endurance of patients subject to extended bed
rest and immobilized limbs, as well as enable longer duration space travel and
exploration.
A major factor in muscular atrophy is increased oxidative stress, where reactive
oxygen species (ROS) induce degradation of muscle fibers[18]. As astronauts travel past
the protection of the Earth’s magnetic field, they experience increased radiation levels
which generate ROS by the radiolysis of water[19]. Even after returning to Earth, ROS
generated by microgravity and irradiation can continue to disrupt cellular systems.
Developing countermeasures for atrophy and radiation in spaceflight will require
extensive screening of promising pharmaceuticals for efficacy, safety, contraindications,
and dosage schedule. Due to the cost of spaceflight and limited crew time aboard the
International Space Station, high throughput screening of pharmaceuticals in actual
microgravity conditions is not economically feasible. We propose a ground-based model,
detailed herein, to mimic both microgravity and radiation and provide a low cost platform
for drug discovery and testing. Anti-atrophy treatments will not only help immobilized
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patients on Earth, but will also be critical for future spaceflight missions beyond low
Earth orbit.
Background
Atrophic conditions can be generated in ground-based laboratories with a rotary
cell culture system (RCCS), developed by Synthecon Inc. in conjunction with NASA to
simulate microgravity[54]. Microgravity is simulated by the rotational motion of the
vessel maintaining cells in a constant state of free fall, similar to what astronauts
experience in orbit around Earth. The RCCS has been used to simulate microgravity in a
variety of cell types, including lymphocytes, osteoblasts, and myoblasts[57–59]. The
C2C12 cell line used in the experiment presented herein is a mouse myoblast line that can
differentiate into contractile skeletal muscle fibers. First cultured in 1977, the C2C12 cell
line produces many of the same proteins as human muscle tissue, making it a suitable
analog for investigation of radiation and atrophic conditions[60].
Harmful radiation in space primarily comes in two forms, gamma rays and high
energy heavy ions[20]. Radiation intensity fluctuates depending on solar activity and
proximity to the Earth. The lowest radiation dose rates occur when in close proximity to
the Earth and during the solar maximum[20]. Gamma rays are a form of electromagnetic
radiation with no mass while high energy heavy ions are atomic nuclei stripped of
electrons and moving at relativistic velocities. Some high energy heavy ions are produced
by the Sun, but most come from distant supernovae.
Relative biological effectiveness (RBE) is a measure of how damaging a
particular type of radiation is to living tissue. Gamma radiation is assigned an RBE of 1
by definition. High energy heavy ions can have RBE values ranging from 20-40,
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indicating significantly more tissue damage for an equivalent dose[21]. Although high
energy heavy ions present a greater health hazard in spaceflight, they are difficult to
simulate in a laboratory and require large particle accelerators to produce. In contrast,
gamma radiation sources are relatively inexpensive and a large body of data exists
regarding epidemiological studies in radiation-exposed humans, rodents, and non-human
primates.
NASA limits astronaut radiation exposure to levels that correspond with a 3%
increase in fatal cancer risk[22]. Long term missions beyond low Earth orbit, such as a
journey to Mars, exceed this limit within a single mission and increase the risk of
developing cancer[20]. Due to the highly penetrating nature of high energy ions in
cosmic radiation, shielding the spacecraft is not economically feasible[20]. Biological
countermeasures to radiation damage and increased cancer risk provide an attractive
alternative to heavy and costly shielding.
One cellular response that counters radiation damage is the up-regulation of heme
oxygenase-1 (HO-1)[23, 24]. HO-1 is induced in response to oxidative stress and
combats this stress in part by degrading heme into biliverdin-IXα, a natural antioxidant
and anti-inflammatory[25]. Artificial induction of HO-1 has demonstrated protective
effects against ionizing radiation in multiple tissue types[24, 26]. We hypothesize that the
cytoprotective effects of HO-1 are due to downstream biliverdin production from heme
catabolism and activation of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway by
the biliverdin reductase cell surface receptor. An alternative treatment could include
supplementation with vitamin E, which attenuates radiation-induced cell death and
scavenges reactive oxygen species[30–32].
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Methods
Cell Culture
C2C12 cell stocks were maintained in their undifferentiated state with Dulbecco's
Modified Eagles Medium (DMEM) and 10% fetal bovine serum (FBS) from HyClone,
GE Healthcare. At passage 7, cells were seeded into the RCCS and control conditions at
2.5x105 cells/mL. Culture conditions were maintained at 37°C and 5% CO2. Cell
counting was performed with a Beckman Coulter ViCell, which uses a Trypan blue
exclusion assay. The cells were seeded into DMEM 10% FBS. Every 3 days, the culture
media was changed for fresh media. On day 6, the media was changed to DMEM 2%
FBS to promote differentiation of the myocytes into myotubes. Experimental cultures
were maintained for a total of 15 days. Experimental conditions were normal gravity,
normal gravity with radiation, simulated microgravity, and simulated microgravity with
radiation. Each condition was cultured in duplicate.
Microgravity Simulation
A Synthecon RCCS-4H with four 10 mL high aspect ratio vessels (HARVs) was
used to generate simulated microgravity conditions [Figure 13A]. Cells were cultured on
5 mg/mL of HyClone HyQ Sphere Pplus 102-L microcarrier beads. Rotation of the
culture vessels was maintained at 10-12 RPM to prevent settling and maintain cells in a
constant state of free-fall. Microcarrier beads in Corning ultra-low attachment tissue
culture flasks provide a normal-gravity control. Shear effects from media flow in the
RCCS are accounted for by placing the control conditions on an orbital shaker plate at am
equivalent RPM [Figure 13B].
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Figure 13. Model setup for microgravity and spaceflight radiation simulation. A – Rotary
cell culture system. B – Normal gravity control. C – Cesium-137 source disks. D – Lead
shielding.
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Radiation Source
Gamma radiation was provided by two Spectrum Technologies cesium-137
source disks attached to the vessels for the duration of the culture [Figure 13C]. The
radioactive source disks were approximately 10 µCi, calibrated to ± 5% according to the
National Institute of Standards and Technology. Dose rate to the cells was 25-30 µSv/hr.
Lead shielding with a thickness of 1.9 cm isolated control conditions from irradiated
conditions, reducing dose rate to 0.5-1 µSv/hr [Figure 13D]. Cumulative dose for the 15
day culture was approximately 10 mSv, equivalent to 24 days on the International Space
station[76].
Spent Media Analysis
Amino acid concentrations in cell culture media from day 15 were determined
with a Waters Alliance 2695 high performance liquid chromatography (HPLC) system.
Analysis of alanine and the branch chain amino acids (BCAAs) leucine, isoleucine, and
valine was conducted. Alanine is secreted into the bloodstream by muscle fibers while
BCAAs are oxidized for nutrients[74, 75]. Lower alanine and BCAA consumption would
indicate decreased metabolic activity, expected in simulated microgravity and irradiated
conditions.
Fluorescent Imaging
Cell morphology, viability, lipid peroxidation, and DNA damage were determined
via fluorescent imaging with a Zeiss confocal microscope. We expect decreased viability,
increased lipid peroxidation from ROS, and double-strand DNA breaks in irradiated
conditions. Simulated microgravity it expected to increase lipid peroxidation due to ROS.
For live cell assays, the cells were rinsed with phosphate buffered saline (PBS) and
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incubated with the dyes for 30 minutes at 37°C before imaging. Live cell imaging for
viability used 1 µM Hoechst 33342, 2.5 µM propidium iodide, and 3 µM Calcein-AM.
Live cell imaging for lipid peroxidation used 1 µM Hoechst 33342, 50 nM MitoTracker
CMX-Ros, and 20 µM dichloro-dihydrofluorescein (DCF).
For the fixed cell DNA damage H2AX assay, cells were first incubated in DMEM
with 50 nM Mitotracker CMX-Ros for 30 minutes at 37°C. The media was removed and
PBS containing 4% paraformaldehyde was added for 15 minutes at room temperature to
fix the cells. The cells were rinsed once with PBS and then permeabilized with 2.5
µL/mL of Triton X-100 in PBS for 15 minutes at room temperature. The fixation buffer
was removed, the cells rinsed again in PBS, and then blocked for one hour with 10
mg/mL of bovine serum albumin in PBS at room temperature to prevent non-specific
binding of the primary antibody. After removing the blocking buffer, the 2 µg/mL of
Anti-phospho-Histone H2AX (Ser139) primary antibody from Millipore, diluted in
blocking buffer, was added for one hour at room temperature. The cells were then rinsed
three times with PBS before adding 1 µg/mL of goat anti-mouse IgG (H+L) secondary
antibody conjugated with Alexa Fluor 488, from Thermo Fisher Scientific. The
secondary antibody was diluted in blocking buffer, along with Hoechst 33342, and
incubated for one hour at room temperature. Finally, the cells were rinsed again three
times with PBS and imaged.
Western Blot
Protein analysis was accomplished using Western blot. Lower concentrations of
the muscle proteins myosin and tropomyosin are expected in simulated microgravity and
irradiated conditions. Intracellular proteins were extracted by lysing the cells while
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adhered to the microcarrier beads. Cells were rinsed with PBS and lysed using a urea
based lysis buffer containing 8M urea, 300mM NaCl, 5mL/L Triton X-100, 50mM
sodium phosphate dibasic, and 50mM Tris-HCl. A protease inhibitor cocktail consisting
of 1mM PMSF and 0.1mg/mL of pepstatin, antipain, and leupeptin was added to the lysis
buffer.
Lysate protein content was determined using a Pierce BCA protein assay kit and a
Thermo Scientific NanoDrop. SDS PAGE was performed using pre-cast 4-20% TrisGlycine gels from NuSep. 20 µg of each sample was loaded onto the gel along with 10
µg of actin and myosin standard from BioRad. After running at 150 V for one hour, the
proteins were transferred to a PVDF membrane using a Pierce fast semi-dry blotter
according to the manufacturer instructions. Primary antibodies MF-20 and CH-1, which
have activity against myosin and tropomyosin, respectively, were purchased from the
Developmental Studies Hybridoma Bank. Antibody concentration was 0.35 µg/mL.
Antibody incubation was performed according to published protocol[77]. The blot was
developed with SuperSignal West Pico Chemiluminescent substrate from Thermo
Scientific and imaged with a Thermo Scientific myECL imager.
Enzyme Linked Immunosorbent Assay
HO-1 was assayed with an IMMUNOSET HO-1 (mouse) ELISA development set
from Enzo Life Sciences. From the cell lysate, 20 µg of total protein, as determined by
BCA assay, was loaded into each well. The plate was developed with 1-Step Turbo
TMB-ELISA substrate from Thermo Scientific and imaged with a SpectraMax M2 plate
reader.
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Results and Discussion
Spent Media Analysis
Slight decreases in alanine concentration for radiation exposed conditions were
observed [Figure 14]. Alanine is not present in DMEM and is released by muscle fibers
into the media as part of the alanine cycle[74]. Reduced alanine secretion indicates fewer
muscle fibers and/or lower metabolic activity, expected for cells under increased stress or
atrophic conditions. Reduced alanine in radiation exposed conditions was in line with
expectations. On the other hand, alanine concentrations in simulated microgravity vs.
normal gravity controls did not follow the expected trend. Cells cultured in simulated
microgravity had higher extracellular alanine concentrations than the normal gravity
controls. Increased sample size is necessary to determine if these results are statistically
significant.

HPLC – Extracellular Alanine, n=2
Conc. (mg/mL)
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Figure 14. Alanine concentrations in spent media harvested on day 15. NG = normal
gravity. MG = microgravity. Error bars are high/low for n=2.
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No significant differences were observed in the concentration of BCAAs. BCAAs
are oxidized during muscle fiber activity[75]. We expected to observe decreased BCAA
consumption in conditions exposed to simulated microgravity. Similar BCAA
consumption across all conditions may be due to insufficient sample size and/or culture
time.
Fluorescent Imaging
Fluorescent imaging for cell viability did not reveal significant differences
between conditions. Differentiation of myocytes into multi-nucleated myotubes was
confirmed for all conditions, demonstrating that simulated microgravity does not prohibit
formation of new muscle fibers. Lipid peroxidation was observed in both normal gravity
controls and simulated microgravity conditions, as indicated by DCF [Figures 15-16].
Radiation provided by the cesium-137 sources induced minor double-strand DNA breaks,
as visualized by H2AX phosphorylation[78] [Figures 17-18]. Stronger radiation sources
are being investigated to provide more significant damage.
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Figure 15. Normal gravity control stained
for nuclei with Hoechst (blue), muscle fibers
with MitoTracker (red), and lipid
peroxidation with DCF (green).

Figure 16. Simulated microgravity control
stained for nuclei with Hoechst (blue),
muscle fibers with MitoTracker (red), and
lipid peroxidation with DCF (green).

Figure 17. No-radiation control under
normal gravity stained for nuclei with
Hoechst (blue), muscle fibers with
MitoTracker
(red),
and
H2AX
phosphorylation (green, not present).

Figure 18. Radiation exposed condition
under normal gravity stained for nuclei with
Hoechst (blue), muscle fibers with
MitoTracker
(red),
and
H2AX
phosphorylation (green, see inset for detail ).
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Enzyme Linked Immunosorbent Assay for Heme Oxygenase-1
HO-1 is upregulated during periods of oxidative stress to catabolize heme into biliverdin,
a natural antioxidant[79]. Due to oxidative stress induced by radiation and the microgravity
environment, we expected to observe an increase in HO-1 for radiation-exposed conditions as
well as cell cultured in simulated microgravity. However, decreased HO-1 in cell lysate was
observed for radiation-exposed conditions [Figure 19]. The large error bars preclude drawing
conclusions regarding HO-1 in simulated microgravity vs. normal-gravity controls until more
data is generated. To maximize protein concentration, undiluted lysate was used for the assay.
Error may be introduced due to the high viscosity of the lysate, resulting in inconsistent
pipetting.

Intracellular HO-1, n=2
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ng/mL
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NG + Radiation
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MG + Radiation

Figure 19. HO-1 ELISA with cell lysate containing 20 µg total protein. NG = normal gravity.
MG = microgravity. Error bars are high/low for n=2.
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Proposed Atrophy and Radiation Countermeasures
Successful development of a ground-based model for microgravity-induced muscle
atrophy and spaceflight radiation would provide a low-cost platform for testing anti-atrophy and
radioprotective drugs. We have identified promising therapeutic compounds to counter cellular
damage from spaceflight conditions. A major contributor to muscular atrophy is the increased
production of tissue-damaging reactive oxygen species following immobilization or disuse,
including disuse stemming from the microgravity conditions of spaceflight[80–82]. Hydrogen
peroxide (H2O2) released from murine mitochondria nearly doubles after two weeks of hind limb
suspension, which in addition to its inherent cytotoxic effects stimulates the release of calpain
and Caspase 3, proteases that degrade myofilaments[83]. Exposure to ionizing radiation also
generates reactive oxygen species via radiolysis of water[19]. Scavenging these reactive oxygen
species would limit calpain and Caspase 3 activation and protect cells from damage.
Mesobiliverdin-IXα
To combat the oxidative stress associated with disuse atrophy of skeletal muscle, we
propose mesobiliverdin-IXα, a microbial-sourced analog of biliverdin-IXα with antioxidant and
anti-inflammatory properties. Biliverdin-IXα cannot be economically extracted from mammalian
cells due to rapid conversion to bilirubin by biliverdin reductase. However, we have isolated
gram quantities of mesobiliverdin-IXα from cyanobacteria bile pigments using a scalable
process. Mesobiliverdin-IXα was found to behave similarly to biliverdin-IXα, including serving
as a substrate biliverdin reductase in human cells[84]. Cytoprotective effects of mesobiliverdinIXα and biliverdin analogs have been demonstrated with pancreatic islet cells, vascular
endothelial cells, and arterial smooth muscle cells[84–86].
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Our preliminary data indicates increased protein production in both normal gravity and
simulated microgravity conditions for cells supplemented with 10 µM of mesobiliverdin-IXα, as
determined by Western blot [Figure 20]. The normal gravity control in this example performed
worse than expected, likely due to mechanical stress from a rocker plate. Current controls are
cultured on an orbital shaker with a fluid motion more similar to that of the RCCS.

Figure 20. A – Myosin and tropomyosin standard. B – Normal gravity control. C – Normal
gravity control with 10 µM mesobiliverdin-IXα. D – Microgravity control. E – Microgravity
with 10 µM mesobiliverdin-IXα.

The direct antioxidant properties of bilirubin and biliverdin-IXα in cell-free systems have
been established[87]. We hypothesize that mesobiliverdin-IXα will exhibit indirect
cytoprotection by moderating expression of heme oxygenase-1, an inducible enzyme which
combats oxidative stress in part by degrading heme into biliverdin-IXα[25]. Elucidating the
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influence of mesobiliverdin-IXα on HO-1 is critical due to the numerous downstream effects of
HO-1 activation. Increasing HO-1 expression with hemin supplementation attenuates
immobilization-induced skeletal muscle atrophy, potentially by preventing protein degradation
from oxidative stress[88].
However, not all of the products of heme degradation are beneficial. In addition to
biliverdin-IXα, heme degradation also results in the production of carbon monoxide (CO) and
iron (Fe2+) [Figure 21]. Contrary to the antioxidant properties of biliverdin-IXα, free Fe2+ can
react with H2O2 to produce a hydroxyl radical[18]. Furthermore, CO inhibits CCAAT-enhancerbinding protein δ from binding to the MyoD promoter [Figure 21], thereby reducing the
differentiation of myoblasts into contractile myotubes[89]. This side effect of the HO-1 oxidative
stress response mechanism is especially detrimental in spaceflight, where significant muscle loss
is experienced despite the current International Space Station exercise program[90].

Figure 21. Heme catabolism pathway with proposed mesobiliverdin route of efficacy
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Mesobiliverdin-IXα may provide the cytoprotective effects of HO-1 without induction of
MyoD inhibition and Fe2+ generation. Activation of cell-surface biliverdin reductase (BVR) has
important downstream consequences, inducing Akt via intracellular phosphorylation of BVR,
which binds to the p85α subunit of PI3K[91]. PI3K activation suppresses phosphatase and tensin
homolog (PTEN), a negative regulator of muscle growth[92]. Furthermore, Akt regulated protein
synthesis pathways are inhibited during periods of inactivity[92]. Activation of the PI3K-Akt
pathway also limits cellular apoptosis following irradiation[93, 94]. Since mesobiliverdin-IXα
serves as a substrate for human BVR[84], we hypothesize that supplementation with
mesobiliverdin-IXα will provide the benefits of increased PI3K and Akt expression. The
prospective action of mesobiliverdin-IXα through the BVR—PI3K—Akt pathway is
encouraging. Activating Akt directly causes feedback inhibition of PI3K, associated with cardiac
dilation and death in the long-term[95, 96]. Since mesobiliverdin-IXα’s action on Akt would be
indirect, we do not anticipate the aforementioned complications.
It will be critical to determine if mesobiliverdin-IXα inhibits HO-1 via a feedback
mechanism. The breakdown of heme is important, as excess heme produces inflammation and
apoptosis in a variety of cell types[97, 98]. If, upon mesobiliverdin-IXα supplementation, HO-1
induction is lessened in response to oxidative stress but not in response to free heme, MyoDinhibiting CO and generation of hydroxyl radicals from Fe2+ will be limited while both the direct
antioxidant properties of mesobiliverdin-IXα and downstream BVR—PI3K—Akt pathways are
maintained.
Vitamin E
Another promising atrophy and radiation countermeasure is vitamin E. The antioxidant
effects of vitamin E scavenge free radicals and reduce expression of calpains and Caspase 3, -9,
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and -12, reducing muscular atrophy due to immobilization and unloading[27, 28]. In addition to
preventing muscle loss, vitamin E also preserves bone mass and strength following
unloading[29]. Several forms of vitamin E have demonstrated radioprotective effects, including
α-tocopherol, δ-tocotrienol, and γ-tocotrienol[30–32]. Unlike mesobiliverdin-IXα, vitamin E
inhibits the PI3K-Akt pathway, which may promote apoptosis of tumor cells[99, 100]. The
effects of combined mesobiliverdin-IXα and vitamin E supplementation will also be
investigated.
Conclusions
The RCCS successfully cultures and permits differentiation of multi-nucleated myotubes,
basic components of muscle tissue. Irradiation for 15 days with 20 µCi of cesium-137 produces
minimal double-stranded DNA breaks. Exposure to radiation resulted in decreased
concentrations of alanine and HO-1, though more data must be generated to determine statistical
significance. Stronger radiation sources are being investigated to provide a dose equivalent to a
journey to Mars within a two week culture period.
The initial data generated since January 2015 are insufficient to determine whether or not
the combination of a RCCS and radiation source provide a platform that generates conditions
mimicking spaceflight. To conclusively demonstrate similarity of the model to spaceflight,
muscle protein concentration must be lower and markers of oxidative stress must be higher in
microgravity and irradiated conditions. Increased expression of the atrophy markers Atrogen-1,
MuRF1, and Nedd4 in simulated microgravity would provide evidence of the model’s
effectiveness[101]. Analysis of these markers with qRT-PCR is ongoing. Culture on flat
membranes instead of microcarrier beads may improve fluorescent imaging results. The Z-stacks
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required for 3D bead clusters can take more than one hour per image, leaving ample time for
cells to undergo changes when performing live cell imaging.
Completion of an in vitro ground-based model for spaceflight atrophy and radiation
injury would provide a valuable platform for testing countermeasures necessary to ensure
astronaut health and fitness during long-term spaceflight. Radiation doses can be tuned to
simulate a variety of mission circumstances from short-term low Earth orbit to multi-year
expeditions on Mars. The metrics presented herein will also elucidate the mechanisms of action
for atrophy and radiation countermeasures, providing a foundation for design and selection of
novel therapeutics.
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CHAPTER 5
FINAL MANUSCRIPT
Muscle atrophy marker expression differs between rotary cell culture system and animal studies

Abstract
Muscular atrophy, defined as the loss of muscle tissue, is a serious issue for immobilized
patients on Earth and in human spaceflight, where microgravity prevents normal muscle loading.
In vitro modeling is an important step in understanding atrophy mechanisms and testing
countermeasures before animal trials. The most ideal environment for modeling must be
empirically determined to best mimic known responses in vivo.
To simulate microgravity conditions, murine C2C12 myoblasts were cultured in a rotary
cell culture system (RCCS). Alginate encapsulation was compared against polystyrene
microcarrier beads as a substrate for culturing these adherent muscle cells. Changes after culture
under simulated microgravity were characterized by assessing mRNA expression of MuRF1,
MAFbx, Caspase 3, Akt2, mTOR, Ankrd1, and Foxo3. Protein concentration of myosin heavy
chain 4 (Myh4) was used as a differentiation marker. Cell morphology and substrate structure
were evaluated with brightfield and fluorescent imaging.
Differentiated C2C12 cells encapsulated in alginate had a significant increase in only
MuRF1 following simulated microgravity culture and were morphologically dissimilar to normal
cultured muscle tissue. On the other hand, C2C12 cells cultured on polystyrene microcarriers had
significantly increased expression of MuRF1, Caspase 3, and Foxo3 and easily identifiable
multi-nucleated myotubes. The extent of differentiation was higher in simulated microgravity
and protein synthesis more active with increased Myh4, Akt2, and mTOR. The in vitro
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microcarrier model described herein significantly increases expression of several of the same
atrophy markers as in vivo models. However, unlike animal models, MAFbx and Ankrd1 were
not significantly increased and the fold change in MuRF1 and Foxo3 was lower than expected.
Using a standard commercially available RCCS, the substrates and culture methods described
only partially model changes in mRNAs associated with atrophy in vivo.
Introduction
Muscle loss from disuse negatively affects quality of life in patients on Earth and remains
a significant risk factor to astronaut health despite rigorous exercise programs onboard the
International Space Station[102, 8]. Approximately 40-50% of total body mass is skeletal muscle
and its loss can induce numerous detrimental physiological changes, including reduced power,
lower endurance, and atypical reflex responses[6, 7]. Disuse, reduced protein synthesis, and
reduced motor neuron activity all contribute to losing muscle tissue and strength in
spaceflight[6]. Atrophy severity varies with microgravity exposure time and anatomical region.
Muscle mass loss for short duration missions ranges from 10-20%, compared to 30-50% for long
duration missions[2, 3]. To reduce these risks, flight protocol at the National Aeronautics and
Space Administration (NASA) mandates that crew members exercise on missions lasting over 10
days; however, loss of strength and muscle mass has been reported after only 5 days[4, 5].
Preserving astronaut strength and endurance by limiting muscle atrophy is critical for enabling
long duration space travel and exploration. To this end, ground-based modeling of microgravity
is a critical step in developing atrophy countermeasures.
Three key mRNAs in muscle loss are muscle RING finger-1 (MuRF1, also called
Trim63), muscle atrophy F-box (MAFbx, also called Fbxo32 and Atrogin-1), and Caspase 3, all
upregulated in numerous rodent models of muscular atrophy including disease, immobilization,
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hind limb unloading, as well as spaceflight[12, 15, 34–45]. MuRF1 and MAFbx are key E3
ubiquitin ligases involved in recycling of muscle proteins[12]. However, intact muscle fibers
cannot be degraded by the ubiquitin proteasome system and must be broken down before MuRF1
and MAFbx can act. This breakdown is induced by Caspase 3, upregulated during muscular
atrophy and responsible for the degradation of actomyosin complexes in the muscle tissue[7, 11].
Following hind limb unloading, knockout mice lacking MuRF1 and MAFbx display significantly
less atrophy than wild type mice, highlighting the importance of those ligases in the mechanisms
underlying muscle loss[12, 35].
Additional mRNAs important for monitoring muscle health include Akt2, Foxo3, mTOR,
and Ankrd1. Akt2 (also called Protein Kinase B β) is a serine/threonine-protein kinase and a
downstream target of insulin-like growth factor (IGF) induced muscle differentiation[103].
Upregulated significantly in differentiated skeletal muscle, the absence of Akt2 leads to a
substantial reduction in myotube diameter[104]. Forkhead Box O3 (Foxo3), another downstream
target of the IGF signaling pathway, is also upregulated during muscle atrophy in vitro and in
vivo[105–107]. Foxo3 is responsible for activation of multiple atrophy-related transcription
factors, including the ubiquitin ligase MAFbx[107]. A third component of the IGF signaling
pathway is mammalian target of rapamycin (mTOR), a regulator of protein synthesis and muscle
hypertrophy that is increased by mechanical stimulation and in the presence of nutrients and
growth factors[108, 109]. Unlike the previously discussed mRNAs, mTOR expression decreases
during muscle atrophy as the ubiquitin proteasome system becomes more active.
Finally, cardiac ankyrin repeat protein (Ankrd1, also called CARP) is upregulated in both
unloading and denervation models in vivo[106, 110]. The increase in Ankrd1 expression during
muscular atrophy has been reported as up to an order of magnitude higher than that of other
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markers such as MAFbx and MuRF1[110]. Furthermore, the aforementioned proteasome-related
markers may only be temporarily upregulated during the initial stages of muscle atrophy, where
Ankrd1 is persistently expressed at high levels[110]. The large, easily detected increase in
Ankrd1 makes it an attractive target for evaluating muscular atrophy models.
A classic method for simulating weightlessness is the hind limb unloading rodent model,
developed at NASA in the 1970’s[33]. In this model, the rodent is affixed in a harness or tail
traction device such that the hind limbs are elevated at a 30° angle[33]. The resulting unloading
induces muscle atrophy in the hind limbs and cephalic fluid shift similar to real microgravity
conditions[33]. However, ground-based animal models differ from human physiology, are more
time consuming, more expensive, and are subject to more regulation than cell culture models,
providing strong motivation to develop other methods. Newly developed therapeutics can be
effectively screened with smaller quantities in cell culture models and safe dose ranges
established prior to testing in vivo. Highly tissue-specific effects can be elucidated without
confounding variables introduced by other systems in the organism. Additionally, cell culture
models enable use of primary human cell lines, increasing biological relevance to humans.
In vitro modeling of microgravity can be conducted with rotary culture systems and
three-dimensional random positioning machines or clinostats[54, 55]. Here, we employ the
RCCS, developed by Synthecon Inc. in conjunction with NASA to simulate microgravity[54]. In
the RCCS, microgravity is mimicked by the rotational motion of the vessel maintaining cells at
their terminal settling velocity, similar to what astronauts experience in orbit around Earth. The
RCCS has been used to simulate microgravity in a variety of cell types, such as lymphocytes,
osteoblasts, and myoblasts, including the C2C12 mouse myoblast cell line used herein[56–59,
73, 111]. The C2C12 cell line differentiates into contractile skeletal muscle fibers and produces
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many of the same proteins and mRNAs as human muscle tissue[60]. Use of a mouse cell line for
in vitro model development and extension also benefits from a large body of literature available
on mRNA expression in live mouse microgravity models, providing information for evaluating
the model’s similarity to in vivo studies. Previously published work with muscle cells, including
C2C12s, in simulated microgravity focused on changes in differentiation induced by culture in
the RCCS[56, 59, 73]. To the best of the authors’ knowledge, no previously published work has
investigated changes in atrophy-specific mRNAs with muscle cell culture in the RCCS.
Standard culture methods for adherent cells in the RCCS employ a substrate to support
growth. Two substrates commonly used in three-dimensional cell culture are microcarrier beads
and alginate encapsulation. Microcarriers are an attractive substrate due to ease of scalability for
producing large quantities of cells for therapeutic applications[69, 70]. As in standard tissue
culture flasks, C2C12 cells differentiate on microcarriers in vitro. The beads offer a wide variety
of surface chemistries tailored to specific cell types and culture conditions[69].
Alternatively, adherent cells can be encapsulated within a several synthetic or naturally
occurring hydrogels[61]. Naturally occurring alginate hydrogel has well established uses for
mammalian cell encapsulation due to low toxicity and gentle gelling conditions[61–66].
Additionally, the high porosity of alginate hydrogels is advantageous for maximizing diffusion
rates and ensuring adequate exchange of nutrients and waste products with the surrounding
culture media[62]. In contrast with microcarrier beads, which can only be seeded with
undifferentiated cells, alginate encapsulation can be performed on both undifferentiated and
differentiated muscle cells. The percentage alginate used for encapsulation can be varied
between 1.5-3% (w/v) depending on the cell type and desired mechanical properties[63–66, 68].
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To preserve bead integrity in the dynamic RCCS environment, we elected to encapsulate cells at
the upper end of this range to maximize mechanical strength of the beads[62].
Here, we propose a ground-based protocol using C2C12 cells and a RCCS to induce
expression of the atrophy-related mRNAs MuRF1, Caspase 3, and Foxo3. Additionally, the
model induces significant changes in Akt2 and mTOR expression. The model is limited by a lack
of significant MAFbx and Ankrd1 expression and low fold changes in MuRF1 and Foxo3. While
not currently suitable for these purposes, with further development we expect that the RCCS can
be improved to more closely match the expression changes of animal hind limb unloading
models.
Materials and Methods
Cell Culture
C2C12 (ATCC CRL-1772, Manassas, VA, USA) cell stocks were maintained in their
undifferentiated state with Dulbecco's Modified Eagles Medium (DMEM) and 10% fetal bovine
serum (FBS) from HyClone, GE Healthcare (Logan, UT, USA). Stocks were passaged at 6070% confluency during scale-up. Cell counting prior to seeding was performed with a Beckman
Coulter Vi-Cell (Indianapolis, IN, USA), which uses a trypan blue exclusion assay. The
experimental conditions consisted of four replicated vessels per run for each condition described
in Table 1. Controls consisted of standard T25 tissue culture flasks for alginate encapsulated
conditions and ultra-low attachment (ULA) tissue culture flasks (Corning, NY, USA) for
microcarrier conditions.
Table 1. Experimental conditions. All cultures had a total duration of 15 days.
Substrate
Alginate
Alginate
Alginate

Cell State at Seeding
Undifferentiated
Undifferentiated
Differentiated

Culture Vessel
Standard T25 (Control)
RCCS
Standard T25 (Control)
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Alginate
Microcarrier
Microcarrier
Microcarrier
Microcarrier

Differentiated
Undifferentiated
Undifferentiated
Undifferentiated
Undifferentiated

RCCS
ULA T25 (Control)
RCCS
Horizontally orientated RCCS (Control)
ULA T25 Days 1-12, RCCS Days 13-15

The use of ultra-low attachment flasks for microcarrier cultures was necessary to prevent
cells from growing on the flask surface, forcing adherence on the microcarrier beads and
ensuring the available surface area for cell growth was identical to the RCCS vessels. Cells were
seeded into each experimental condition of Table 1 at 2.5x105 cells mL-1 with a total volume of
10 mL. Culture conditions were maintained at 37°C and 5% CO2. Every 3 days, the culture
media was changed for fresh media. On day 6, the media was changed to DMEM 2% FBS to
promote differentiation of the myocytes into myotubes. All cultures were maintained for a total
of 15 days. The 15 day culture time was selected to maximize exposure to the simulated
microgravity environment while preventing loss of cell attachment from microcarriers,
previously reported for longer duration cultures[112]. For the final condition in Table 1, the cells
were moved from ULA T25s to the RCCS for the final 3 days of the culture period.
Microgravity Simulation
A Synthecon RCCS-4H (Houston, TX, USA) with four 10 mL high-aspect-ratio vessels
(HARVs) was used to generate simulated microgravity conditions. Sterilization and operation of
the Synthecon RCCS-4H was carried out in accordance with the manufacturer’s instructions.
Vessel rotation was adjusted empirically to maintain the majority of the substrate in suspension,
as described in Table 2. The horizontally orientated RCCS, investigated as a normal gravity
control, was maintained at the mean RPM of 15. When the substrates are maintained at their
terminal settling velocity, the force of gravity 𝐹𝑔 is described by Stoke’s Law (Equation 1).
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𝐹𝑔 = (𝜌𝑎 − 𝜌)𝑔 𝜋𝑅 3
3

(1)

In Equation 1, 𝜌𝑎 is the density of the cell aggregate, 𝜌 is the density of the culture media, 𝑅 is
the radius of the cell aggregate and 𝑔 is the force of gravity. The resulting 𝐹𝑔 is balanced by the
drag force from the rotating fluid, resulting in a net force of zero. Since 𝑔 and 𝑅 are constant at
any given moment, the ratio of 𝐹𝑔 in the RCCS to the normal force of gravity can be simplified to
express how many times normal gravity (𝑋𝑔) is produced within the system, as described by
Equation 2 and detailed in Table 2.
𝑋𝑔 = 𝐹

𝐹𝑔 𝑅𝐶𝐶𝑆
𝑔 𝑁𝑜𝑟𝑚𝑎𝑙

=

𝜌𝑎 −𝜌
𝜌𝑎

(2)

Table 2. The RCCS rotation rate necessary to maintain the substrates in suspension varies with
diameter. Times Earth Gravity varies with substrate density. aMicrocarrier initial diameter at
seeding. bMicrocarrier cluster diameter at harvest. Data displayed as mean ± CV, n=10.
Substrate
Density (g cm-3) 𝑋𝑔 Diameter (µm)
RPM
a
b
Microcarriers 1.02
0.02 160±18.7% to 698±10.5% 10-20
Alginate
1.07
0.07 3252±3.2%
35

Microcarriers
Undifferentiated C2C12 cells were cultured on 5 mg mL-1 of HyClone HyQ Sphere Pplus
102-L microcarrier beads. These polystyrene beads have a cationic surface charge and are well
suited for culturing cells in agitated vessels with serum-containing media[69]. Rotation of the
culture vessels was initiated at 10 RPM and increased up to 20 RPM as the culture age increased
and amalgamations of beads formed. Vessel RPM was adjusted empirically to prevent settling
and maintain the beads suspended at their terminal settling velocity. Microcarrier beads in static
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ULA T25 tissue culture flasks provided a normal-gravity control and produced microcarrier
cluster sizes similar to those in the RCCS.
Alginate Encapsulation
Undifferentiated C2C12 cells were mixed with 3% (w/v) solution of high viscosity
alginate (MP Biomedicals, Santa Ana, CA, USA) at a density of 10x106 cells mL-1. Beads were
formed by dripping the alginate-cell mixture into 200 mM CaCl2 10mM HEPES at pH 7 through
a 19-gauge syringe needle at a flow rate of 2 mL min-1. The beads were cured in CaCl2 buffer for
20 minutes at 37°C. Once cured, the average bead diameter was 3252±103 µm with a volume of
approximately 18 µL, yielding 1.8x105 cells per bead. To match the seed volume of the
microcarriers, 14 alginate beads were used per 10 mL vessel. The beads were rinsed once with
DPBS and transferred to their respective culture conditions in DMEM 10% FBS.
Differentiated cells were encapsulated following 9 days of growth in standard tissue
culture flasks. The myotubes were removed from the flask with a cell scraper and re-suspended
at a density of 75 cm2 culture area per mL of alginate. Subsequent alginate encapsulation
methods were performed as described for undifferentiated cells.
Upon harvest, the alginate beads were dissolved with 100 mM sodium citrate, 150 mM
NaCl, 30 mM EDTA at pH 7.0 and 37°C. The cells were pelleted via centrifugation and rinsed
with DPBS before proceeding with RNA extraction, as described in the following section.
Atrophy Marker Expression
Relative expression of the atrophy markers MuRF1, MAFbx, and Caspase 3 was
determined using RT2 qPCR primer assays from Qiagen (Hilden, Germany). Akt2, mTOR,
Foxo3, and Ankrd1 primers were purchased from Bio Rad (Hercules, CA, USA). RNA
extraction was carried out immediately upon culture harvest using the illustra RNAspin Mini Kit
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according to the manufacturer’s instructions (GE Healthcare, Marlborough, MA, USA).
Extracted RNA was quantified with a NanoDrop (Thermo Fisher Scientific, Waltham, MA,
USA) and converted to cDNA with the RT2 First Strand Kit from Qiagen. All PCR reactions
were loaded with 5 ng of cDNA and SYBR Green ROX qPCR Mastermix from Qiagen.
Fluorescence was read with an Eppendorf Mastercycler realplex4 (Hamburg, Germany). Cycle
settings were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, then 60°C for
1 minute. Analysis was performed using the default noise band threshold with drift correction
applied in Eppendorf Mastercycler realplex 2.2 software. All results were normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a suitable housekeeping gene for
atrophying muscle tissue in vitro and in vivo[113–118]. GAPDH expression in our samples was
stable, with a CV of 2.5% for all microcarrier samples and 3.7% for all alginate samples.
Normalization was calculated with the 2ΔΔCt method[119].
Microscopy
Brightfield microscopy was performed using an AMG EVOS xl from Thermo Fisher
Scientific to assess encapsulated cell distribution and alginate bead size and shape. The beads
were then fixed in cold methanol for 30 minutes at -20°C, transferred to a solution of 30%
sucrose 0.1M CaCl2 overnight at 4°C, then frozen in Tissue-Plus O.C.T. compound (Fisher
Scientific, Pittsburg, PA, USA) at -20°C until sectioning[120]. Using a Leica CM1850 cryomicrotome (Wetzlar, Germany), the beads were sliced into 30 µm sections and mounted on
Fisher SuperFrost Plus slides, treated with 1 µM Hoechst 33342 (Invitrogen, Carlsbad, CA,
USA) to visualize the nuclei and imaged with an Observer Z1 confocal microscope (Zeiss,
Oberkochen, Germany).
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Cell morphology for microcarriers was also evaluated via fluorescent imaging with the
Observer Z1 confocal microscope. Microcarrier-cell clusters were first rinsed with DPBS, then
incubated with 1 µM Hoechst 33342 and 50 nM MitoTracker CMX-Ros (Invitrogen, Carlsbad,
CA, USA) for 1 hour at 37°C. The clusters were rinsed again with DPBS and z-stack images
were acquired with a 3 µm step size. Diameter of multi-nucleated muscle fibers growing on the
microcarriers was determined with ImageJ.
Protein Assay
Extent of terminal differentiation was quantified by ELISA for mouse myosin heavy
chain 4 (Myh4) (Biomatik, Wilmington, DE, USA), present in high levels in fused
myotubes[121]. Cells were rinsed with PBS and lysed using a urea-based lysis buffer containing
8 M urea, 300 mM NaCl, 5mL L-1 Triton X-100, 50 mM sodium phosphate dibasic, and 50 mM
Tris-HCl. A protease inhibitor cocktail consisting of 1 mM PMSF and 0.1mg mL-1 of pepstatin,
antipain, and leupeptin was added to the lysis buffer. The cells were lysed on the microcarriers
and the lysate was isolated by centrifugation. Lysate protein content was determined using a
BCA protein assay kit (Pierce, Rockford, IL, USA) and a SpectraMax i3x (Molecular Devices,
San Jose, CA, USA). Lysates were diluted to 1 µg mL-1 total protein with PBS and the ELISA kit
ran according to the manufacturer’s instructions. Quantitation was performed using the
Spectramax i3x.
Statistics
Graphical data are presented as the means ± standard deviation. Significance was
determined by comparing data sets with Student’s t-test. Differences were considered significant
at P < 0.05.
Results
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Microcarrier Substrate Structure & Cell Morphology
When cultured on HyQSphere Pplus 102-L microcarriers, C2C12 cells form monolayers
over the bead surface (Figure 22). Differentiated, multi-nucleated myotubes were observed
spanning across beads (Figure 22A, C). No significant difference was observed in differentiation
or number of multi-nucleated myotubes between simulated microgravity and normal gravity
controls. The irregular three-dimensional structure of the bead amalgamations was best
visualized with brightfield microscopy (Figure 22B, D). Microcarrier bead cluster size increased
with culture age in both normal gravity controls and simulated microgravity conditions. Due to
the lack of agitation, maximum cluster size was larger in normal gravity controls than in the
RCCS. Additionally, bead clusters formed in normal gravity had widely varying, irregular shapes
compared to consistently rounded bead clusters formed in the RCCS (Figure 22 A, B vs. C, D).
Despite variations in cluster size and shape, no significant differences in cell morphology were
observed. Muscle fiber diameter was 12.7±6.0 µm and 9.5±1.7 µm for normal gravity controls
and simulated microgravity conditions, respectively. Fiber diameters were more consistent in the
RCCS, but the difference between conditions was not significant (p>0.05, n=10).
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Figure 22. Microcarrier bead clusters after 15 days of culture, imaged at 10x magnification.
Nuclei are stained blue with Hoechst 33342. Mitochondria are stained red with MitoTracker
CMX-Ros. Normal gravity (A, B) and simulated microgravity (C, D) bead clusters both have
differentiated, multi-nucleated myotubes spanning across bead gaps (white arrows). Scale bar =
100 µm.
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Alginate Substrate Structure & Cell Morphology
Undifferentiated cells encapsulated in alginate were evenly distributed throughout the
bead (Figure 23A), where encapsulation of differentiated cells resulted in irregular sheets with
uneven distribution (Figure 23B). A section of an alginate bead containing differentiated cells
reveals the encapsulation process forces the harvested muscle fibers into atypical configurations
(Figure 23C), compared to the regular, parallel orientation common in standard tissue culture
flasks (Figure 23D). For cells encapsulated in their undifferentiated state, minimal differentiation
was observed after 15 days of culture. No differences in cell morphology were observed between
the RCCS and normal gravity controls. Alginate bead degradation was minimal, as more than
90% of the beads were intact when they were harvested at the end of the culture period.
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Figure 23. Alginate encapsulated undifferentiated (A) and differentiated cells (B) imaged at 2x
magnification, scale bar = 1000 µm. Interior morphology of encapsulated differentiated cells in a
30 µm section of an alginate bead (C) compared to a standard T25 (D), scale bar = 100 µm.
Nuclei are stained blue with Hoechst 33342 (C & D). Mitochondria are stained red with
MitoTracker CMX-Ros (D only).

Atrophy Marker Expression
Alginate-encapsulated differentiated cells in the RCCS expressed significantly more
MuRF1 than those in T25s, but the difference in MAFbx and Caspase 3 expression was not
significant (Figure 24). Encapsulated undifferentiated cells in the RCCS expressed significantly
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less MuRF1, MAFbx, and Caspase 3 than those in T25s, contrary to the hypothesized response
(Figure 24).
When cultured on microcarriers, expression of MuRF1 and Caspase 3 was significantly
elevated after 12 days in ULA T25s, followed by 3 days in the RCCS, relative to ULA T25
control flasks (Figure 24). Cultures that remained in the RCCS for 15 days also expressed
significantly more MuRF1 and Caspase 3 than the ULA T25 control. The change in MAFbx was
not significant for either simulated microgravity culture method but was larger for the ULA T25
(12 days) + RCCS (3 days) condition (p=0.1). Significance for all comparisons is detailed in
Table 3.
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Figure 24 Average ± s.d. fold change in expression of mRNAs for alginate and microcarrier
cultures, relative to their respective normal gravity controls (alginate N=4, microcarrier N=20)
and normalized by GAPDH. * p<0.05, ** p<0.01, *** p<0.001. No marker = not significant.
N=4 (alginate differentiated), N=4 (alginate undifferentiated), N=16 (RCCS), and N=8 (ULA
T25 + RCCS). All replicates are biological replicates and significance was determined by t-test.
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Table 3. Significance of microcarrier culture mRNA expression changes, as determined by
Student’s t-test. N=20 for ULA T25, N=16 for RCCS, N=8 for ULA T25 + RCCS, and N=4 for
Horizontal RCCS. ns = not significant, * p<0.05, ** p<0.01, *** p<0.001. All replicates are
biological replicates.
MuRF1
ULA T25
RCCS
Horiz. RCCS
ULA T25 + RCCS

ULA T25
—
***
***
**

RCCS
***
—
ns
**

Horiz. RCCS
***
ns
—
***

ULA T25 + RCCS
**
**
***
—

MAFbx
ULA T25
RCCS
Horiz. RCCS
ULA T25 + RCCS

ULA T25
—
ns
ns
ns

RCCS
ns
—
**
***

Horiz. RCCS
ns
**
—
***

ULA T25 + RCCS
ns
***
***
—

Caspase 3
ULA T25
RCCS
Horiz. RCCS
ULA T25 + RCCS

ULA T25
—
***
***
***

RCCS
***
—
ns
ns

Horiz. RCCS
***
ns
—
*

ULA T25 + RCCS
***
ns
*
—

Cells cultured in the RCCS for 15 days and those cultured in the RCCS for only 3 days
following 12 days in ULA T25’s had similarly significant increases in the key atrophy markers
MuRF1 and Caspase 3. Due to shorter duration of RCCS culture, using the latter method allows
for higher throughput testing in a given timeframe, as subsequent cultures need only be staggered
by 3 days instead of 15. Therefore, the ULAT25 + RCCS method was selected for further
development of the model and evaluation of Akt2, mTOR, Ankrd1, and Foxo3. Akt2, mTOR,
and Foxo3 increased significantly in simulated microgravity, but the change in Ankrd1 was not
significant (Figure 25).
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Figure 25. Average ± s.d. fold change in expression of mRNAs for ULA T25 + RCCS simulated
microgravity cultures (N=8) relative to ULA T25 normal gravity control (N=20) and normalized
by GAPDH. * p<0.05, ** p<0.01, *** p<0.001. All replicates are biological replicates and
significance was determined by t-test. Change in MAFbx and Ankrd1 not significant.

Protein Concentration
Myosin heavy chain 4 (Myh4) was used to assess the extent of terminal differentiation. After 15
days of culture on microcarriers in ULA normal gravity control flasks, Myh4 concentration was
1.22±0.26 ng µg-1 total protein. Cells cultured in the RCCS for the final 3 days following 12 days
in the ULA flasks had an Myh4 concentration of 2.13±0.48 ng µg-1 total protein. The difference
between the normal gravity and simulated microgravity conditions was significant (p<0.05,
N=4).
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Discussion
We hypothesized that alginate encapsulated cells would exhibit more significant
increases in atrophy marker expression than cells cultured on microcarriers, since an
encapsulated three-dimensional mass of differentiated muscle tissue may exhibit greater inherent
similarity to animal models than monolayers on the exterior of microcarriers. However, the
alginate-encapsulated differentiated cells only exhibited an increase in MuRF1. Further,
encapsulated undifferentiated cells had significantly lower expression of MuRF1, MAFbx, and
Caspase 3 in simulated microgravity, which was the opposite of expected results (Figure 24).
Low expression of atrophy markers for encapsulated undifferentiated cells may be due to
insufficient myotube formation. The solid alginate structure limits cell-cell contact and
morphology remained consistent over the 15 day culture period (Figure 23A). On the other hand,
C2C12 cells cultured on polystyrene microcarrier beads for 12 days in ULA T25 flasks followed
by 3 days in the RCCS significantly (p<0.05) express more MuRF1, Caspase 3, Akt2, mTOR,
and Foxo3 than the normal gravity control of cells cultured in static ULA T25s for all 15 days,
highlighting the early upregulation of these markers in simulated microgravity (Figure 24).
The timing of maximum MAFbx and MuRF1 expression has in vivo remains under
investigation. Elevated expression has been reported at 3 days, 7 days, and 6 weeks, though
differences in animal line and immobilization methods may be responsible[42, 44, 45]. Unlike
MAFbx and MuRF1, in vivo atrophy models produce consistent significant increases in Caspase
3 over 5, 10, and 14 days[40, 41]. Our results in vitro indicate that MuRF1 expression is higher
in cells cultured for 15 days in the RCCS, compared to 3 days in the RCCS after 12 days in ULA
flasks, while Caspase 3 expression does not change significantly (Figure 24 & Table 3). We did
not observe a significant change in MAFbx at either 3 or 15 days in simulated microgravity,
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suggesting that the timing of upregulation differs from its partner E3 ligase MuRF1. In addition
to the uncertain timing of peak upregulation, this discrepancy in MuRF1 and MAFbx
upregulation may be due to the different roles of the two ligases. While MuRF1 and MAFbx
both play an important part in the ubiquitin proteasome system, MuRF1 is more closely
associated with degradation of myofibers, where MAFbx attenuates new protein synthesis and is
not correlated with atrophy in every case[122, 123].
Increased expression of Akt2 and higher Myh4 concentrations in simulated microgravity
indicate a higher percentage of differentiated cells compared to the normal gravity controls.
mTOR, expected to be lower in simulated microgravity, instead increased significantly after 3
days in the RCCS (Figure 25). Additionally, while Foxo3 will activate MAFbx, Foxo3 was
significantly upregulated while MAFbx—responsible for attenuating protein synthesis—was not
(Figure 25) [107, 122]. Taken together, these results indicate that while the cells in simulated
microgravity were undergoing atrophy—indicated by MuRF1, Caspase 3, and Foxo3—mTOR
mediated protein synthesis and formation of new myotubes had not yet ceased.
Compared to in vivo methods, including casting, tenotomy, and hind limb unloading, our
in vitro model resulted in a similar fold change in Caspase 3 and lower but still statistically
significant increases in MuRF1 and Foxo3 (Table 4). While Caspase 3 is most strongly
upregulated, apoptosis from shear forces is not likely due to the low shear environment of the
RCCS[54]. The fold increase in MuRF1 after 12 days in normal gravity and 3 days in the RCCS
was closer to that of 3 days post-tenotomy rather than 3 days post-immobilization via casting
(Table 4). The in vitro model did not significantly increase MAFbx, but again the fold change
was closer to that following tenotomy. In contrast to the large increase in Ankrd1 seen in vivo,
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our in vitro model did not produce any significant changes (Table 4). While Ankrd1 is expressed
in C2C12 cells, it was not significantly upregulated in this model[124, 125].

Table 4. Fold change in gene expression of atrophy-indicating mRNAs from this in vitro study
(ULA T25 12 days + RCCS 3 days) compared to referenced work in vivo, as measured by qPCR.
ns = not significant, ** p<0.01, *** p<0.001.
In Vitro
MuRF1
1.3**
MAFbx
1.3ns
Caspase 3 3.8***
Ankrd1
1.1ns
Foxo3
1.4**

In Vivo
1.9, 1.6[45]
2.7, 1.5[45]
1.0, 3.3[45]
3.9[106]
1.6[106]

In Vivo method
Casting 3 days, tenotomy 3 days
Casting 3 days, tenotomy 3 days
Casting 3 days, tenotomy 3 days
Hind limb unloading 6 days
Hind limb unloading 6 days

Turning the RCCS horizontal was investigated as a normal gravity control to account for
the effects vessel geometry and fluid motion not present in static ULA tissue culture flasks.
Despite these benefits, the horizontal RCCS was an ideal control due to significant differences in
microcarrier bead cluster morphology and higher MuRF1 expression levels compared with the
simulated microgravity conditions (RCCS, ULA T25 + RCCS) (not shown). Additionally,
microcarrier beads in the horizontal RCCS adhered to the silicone gas transfer membrane,
resulting in large sheets of cells not representative of the bead clusters in Figure 22. Shear forces
from fluid motion in the RCCS are minimal and selecting a control with similar cluster
morphology and consistently significant differences in mRNA expression is preferred[54].
Microcarrier beads and alginate encapsulation each have advantages and disadvantages in
maximizing similarity with in vivo hind limb unloading methods. The advantages of
microcarriers include ease of handling, live cell fluorescent imaging capability, and most
importantly, that they support atrophy marker changes in C2C12 cells. Culture procedures with
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microcarrier beads are simpler and more rapid than alginate encapsulation. The small size of the
beads allows them to be transferred between containers via pipette. Harvest of RNA can be
accomplished by adding the cell-covered microcarriers directly to the lysis buffer, reducing
process time and opportunity for RNase activity. Most critically, simulated microgravity culture
of C2C12 cells on microcarriers resulted in significant expression changes in multiple atrophy
markers compared to the normal gravity control (Figure 25). However, MAFbx and Ankrd1
were not significantly upregulated and the fold increase in MuRF1 and Foxo3 were low,
indicating that this model is incomplete when compared to atrophy modeling in vivo (Table 4).
Microcarriers carry some additional disadvantages regarding the culture method and
morphology. The monolayer of tissue that forms over the bead surfaces does not replicate threedimensional mature tissue in vivo. Compared to astronauts that begin with differentiated muscle
tissue, microcarriers are first seeded with undifferentiated myoblasts which form multi-nucleated
myotubes during culture. Despite this difference, the model remains clinically relevant as fusion
and differentiation of muscle cells are important parts of myogenesis in adults[126]. Another
disadvantage of microcarriers is the large variations in cluster diameter relative to alginate beads
(Table 2). As settling rate within the RCCS varies with substrate diameter, a portion of the
microcarrier clusters will not be maintained at the optimal settling rate to simulate microgravity.
Additionally, bead cluster size increases over time, requiring daily monitoring and RPM
adjustment.
While alginate did not support the desired changes in atrophy marker expression, it offers
some beneficial properties compared to microcarriers. Alginate encapsulation of differentiated
cells in a three-dimensional conformation improves morphological biosimilarity to mature tissue.
However, the current implementation resulted in muscle fiber conformations not typical in vivo
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(Figure 23C). Encapsulation also protects cells from exposure to mechanical stress within the
RCCS. Fluid flow in the RCCS is designed to provide a low shear environment[54]. Still, cells
experience mechanical stress from collisions of suspended substrates due to the rotation of the
system. While cells encapsulated in alginate are protected from direct contact, the exposed nature
of cells cultured on microcarriers means that collisions between beads will result in a direct
impact to the cells. Furthermore, alginate beads have a more consistent size than microcarrier
bead clusters and did not display the same variations in settling rate or require changes in the
RCCS’ RPM (Table 2).
The downsides of alginate, in addition to the lack of significant changes in atrophy
marker expression, stem from their density, size, and opacity. While the solid structure of
alginate protects cells from mechanical stress, it also limits the spreading of encapsulated cells,
preventing formation of intercellular junctions necessary for myoblast fusion (Figure 23A). In
contrast to the small and easy to handle microcarriers, alginate beads, with a diameter of
3252±103 µm, were too large to be aspirated into a pipette. Smaller alginate beads can be formed
by using a higher gauge needle, but narrower needles were clogged by the large sheets of
differentiated muscle tissue seen in Figure 23B. The large bead size also complicated imaging
due to the opacity of alginate, which scattered too much light to allow fluorescent imaging of the
interior without fixation and sectioning. While these issues are addressable with process
modifications, the most significant issue is that nutrient and waste diffusion rates are dependent
on depth, such that beads with tissues closer to the surface may behave differently than those
with tissues encapsulated in the center. As the position of tissues within the bead is random, we
attribute some of the variability in encapsulated differentiated samples to uneven distribution of
tissues within the alginate beads.

72

Overall, culturing with microcarrier beads provides a better platform than alginate
encapsulation for modeling muscular atrophy in C2C12 cells, though this model does not
completely mimic the mRNA changes seen in vivo. Cultures on microcarrier beads resulted in
irregular clusters covered with a monolayer of cells and sporadic myotubes (Figure 22) and
appropriate atrophy marker expression to mimic in vivo studies only with regard to MuRF1,
Caspase 3, and Foxo3, albeit with lower—but still significant—fold changes for MuRF1 and
Foxo3 (Table 4). On the other hand, cultures with encapsulated cells resulted in static, regularly
dispersed undifferentiated cells (Figure 23A) or unevenly dispersed sheets of differentiated tissue
(Figure 23B) without consistent increases in expression of the selected atrophy markers.
Therefore, we conclude that an in vitro model of microgravity-induced muscle atrophy using
polystyrene microcarrier beads is superior to alginate encapsulation for cultured C2C12 cells, but
not sufficient to mimic all of the select atrophy markers as in animal studies. Of the culture
methods evaluated, the most significant and consistent increase in the selected atrophy markers,
relative to GAPDH (Figure 25) was achieved with microcarriers cultured in static ULA flasks for
12 days, then moved to the RCCS for the final 3 days.
Our verification that the RCCS can produce increases in atrophy-specific mRNAs in
cultured muscle cells is an important step towards completing a comprehensive ground-based in
vitro model for spaceflight atrophy. Due to the lower number of atrophy markers upregulated
and the lower fold changes in expression, relative to animal models, we believe the standard
commercially available RCCS is not sufficient for use in vitro atrophy modeling and it does not
match results in vivo. Nevertheless, our results in vitro are highly significant for MuRF1
(p<0.01), Foxo3 (p<0.01), and Caspase 3 (p<0.001), indicating that with further development,
simulated microgravity systems may present a promising platform for investigation of atrophy

73

pathways and first-step design and selection of novel therapeutics necessary to ensure astronaut
health and fitness during long-term spaceflight.

CHAPTER 6
CLOSING REMARKS

Overall, culturing with microcarrier beads provides a better platform for modeling
microgravity-induced muscular atrophy with C2C12 cells than alginate encapsulation. Cultures
on microcarrier beads resulted in irregular clusters covered with a monolayer of cells and
sporadic myotubes, but allowed for ease of handling and, most importantly, resulted in
appropriate atrophy marker expression to mimic hind limb unloading studies with regard to
several key markers. On the other hand, cultures with encapsulated cells resulted in static,
regularly dispersed undifferentiated cells or unevenly dispersed sheets of differentiated tissue
without consistent increases in expression of the selected atrophy markers. Therefore, we
conclude that an in vitro model of microgravity-induced muscle atrophy using polystyrene
microcarrier beads is superior to alginate encapsulation for cultured C2C12 cells. To induce the
most significant and consistent increase in these same atrophy markers, relative to GAPDH, a
normal gravity control with microcarriers in static ULA flasks should be cultured for 15 days and
compared with microcarriers cultured for 12 days in the same flasks, then moved to the RCCS
for the final 3 days.
Due to variations in microcarrier bead cluster size, not all of the cells are maintained at
the optimal settling rate to simulate microgravity. Despite the presence of such variations,
C2C12 cells cultured on microcarriers in the RCCS for 3 days expressed significantly more
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MuRF1, MAFbx, and caspase-3 than normal gravity controls. Alginate beads, having a more
consistent size, did not display the same variations in settling rate. However, neither
undifferentiated nor differentiated cells expressed significant increases in all three mRNA
markers.
The verification that the RCCS can partially model atrophic conditions in cultured muscle
cells is an important step towards completing a comprehensive ground-based in vitro model for
spaceflight atrophy. Our ongoing work focuses on evaluating the effectiveness of antioxidants in
attenuating the increase in MuRF1, MAFbx, and Caspase 3 seen with C2C12 cells cultured in
simulated microgravity on microcarriers. We are also investigating adding radiation to more
accurately simulate spaceflight conditions. The simulated microgravity model described herein
produces increases in the same mRNA markers of muscular atrophy as in vivo hind limb
unloading models, presenting a promising system for investigation of atrophy pathways and firststep design and selection of novel therapeutics necessary to ensure astronaut health and fitness
during long-term spaceflight. Further development of the model with additional cell types,
optimized encapsulation and additional microcarrier materials could improve biosimilarity.
Combined with PCR arrays targeting a large number of genes, the model presented herein can
help elucidate the mechanisms of action for atrophy countermeasures, providing a foundation for
design and selection of novel therapeutics.
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APPENDICES
RCCS OPERATION WITH MICROCARRIERS AND ALGINATE

Lab protocols for operation of the Synthecon RCCS-4H, use of microcarrier beads, and
alginate encapsulation are demonstrated in the video linked below. Demonstration and filming
by Charles P. Harding, editing by Matt Clegg.
https://usu.box.com/s/pdtf48bzqcyank1mskkg2j1dcefeu7y2

